@article{39ad01f044304f808834ac9eb33f5342,
title = "Conventional Anti-CD45 Radioimmunotherapy Comparing 90Y or 177Lu for Treatment of AML in a Syngeneic Disseminated Murine Leukemia Model,",
author = "Orozco, \{Johnnie J.\} and Aimee Kenoyer and Amanda Axtman and Frayo, \{Shani L.\} and Morris, \{Paul J.\} and Hamlin, \{Donald K.\} and Wilbur, \{D. Scott\} and Fisher, \{Darrell R.\} and Hylarides, \{Mark D.\} and Green, \{Damian J.\} and Gopal, \{Ajay K.\} and Ted Gooley and Press, \{Oliver W.\} and Pagel, \{John M.\}",
note = "Abstract 3636 PURPOSE: Radioimmunotherapy (RIT) studies for the treatment of acute myeloid leukemia (AML) have mostly employed antibodies (Ab) labeled with 131I or 90Y, but both radionuclides have limitations. The high-energy gamma component of 131I requires that patients be treated in isolation to minimize radiation exposure risk to staff and family, warranting consideration of alternative radionuclides.",
year = "2011",
month = nov,
day = "18",
language = "American English",
volume = "118",
journal = "Blood",
}